Ferric Carboxymatose in Non-Hemodialysis CKD Patients: A Longitudinal Cohort Study

Autor:	Luca De Nicola, Giuseppe Conte, Nicola Peruzzu, Antonella Netti, Maria Elena Liberti, Roberto Minutolo, Francesco Locatelli, Lucia Del Vecchio, Silvio Borrelli, Patrizia Berto, Carlo Garofalo
Přispěvatelé:	Minutolo, R., Berto, P., Liberti, M. E., Peruzzu, N., Borrelli, S., Netti, A., Garofalo, C., Conte, G., De Nicola, L., Del Vecchio, L., Locatelli, F.
Rok vydání:	2021
Předmět:	medicine.medical_specialty Anemia medicine.medical_treatment 030232 urology & nephrology lcsh:Medicine 030204 cardiovascular system & hematology urologic and male genital diseases Gastroenterology Article Peritoneal dialysis FERRIC CARBOXYMALTOSE 03 medical and health sciences iron deficiency 0302 clinical medicine hemic and lymphatic diseases Internal medicine medicine biology business.industry lcsh:R General Medicine Iron deficiency medicine.disease anemia ferric carboxymaltose female genital diseases and pregnancy complications Ferritin biology.protein Ferric Hemodialysis Hemoglobin business chronic kidney disease medicine.drug
Zdroj:	Journal of Clinical Medicine Volume 10 Issue 6 Journal of Clinical Medicine, Vol 10, Iss 1322, p 1322 (2021)
ISSN:	2077-0383
Popis:	No information is available on the efficacy of ferric carboxymaltose (FCM) in real-world CKD patients outside the hemodialysis setting. We prospectively followed 59 non-hemodialysis CKD patients with iron deficient anemia (IDA: hemoglobin < 12.0/< 13.5 g/dL in women/men and TSAT < 20% and/or ferritin < 100 ng/mL) who were intolerant or non-responders to oral iron. Patients received ferric carboxymaltose (FCM) (single dose of 500 mg) followed by additional doses if iron deficiency persisted. We evaluated efficacy of FCM in terms of increase of hemoglobin, ferritin, and TSAT levels. Direct and indirect costs of FCM were also analyzed in comparison with a hypothetical scenario where same amount of iron as ferric gluconate (FG) was administered intravenously. During the 24 weeks of study, 847 ± 428 mg of FCM per patient were administered. IDA improved after four weeks of FCM and remained stable thereafter. At week-24, mean change (95%CI) from baseline of hemoglobin, ferritin and TSAT were +1.16 g/dL (0.55–1.77), +104 ng/mL (40–168) and +9.5% (5.8–13.2), respectively. These changes were independent from ESA use and clinical setting (non-dialysis CKD, peritoneal dialysis and kidney transplant). Among ESA-treated patients (n = 24), ESA doses significantly decreased by 26% with treatment and stopped either temporarily or persistently in nine patients. FCM, compared to a FG-based scenario, was associated with a cost saving of 288 euros/patient/24 weeks. Saving was the same in ESA users/non-users. Therefore, in non-hemodialysis CKD patients, FCM effectively corrects IDA and allows remarkable cost savings in terms of societal, healthcare and patient perspective.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26c856307e67187fea074ba0275c2e73 https://doi.org/10.3390/jcm10061322 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.